Does Texas Medicaid Cover Weight Loss Medications Like Semaglutide?
Texas Medicaid's coverage of GLP-1 medications like semaglutide is limited - but Houston-area patients have options. Here's what you need to know.
Reviewed for accuracy against current FDA guidance, peer-reviewed clinical trial data (STEP, SURMOUNT trials), and manufacturer prescribing information. See our editorial standards.
Texas Medicaid does not cover semaglutide or any GLP-1 medication strictly for weight loss — but patients with a documented Type 2 diabetes diagnosis have a legitimate path to coverage that many Houston enrollees don't realize exists. Ozempic, approved for diabetes management, clears a different bar than Wegovy, which is approved only for obesity and remains excluded from Texas Medicaid's covered drug list. How your physician codes your diagnosis and documents your medical history makes a real difference in what gets approved, which is why patients across Houston, Sugar Land, and The Woodlands are getting very different answers from their plans. This article covers exactly where the coverage lines are drawn, which managed care plans have more flexibility, and what steps you can take now to build a stronger case with your provider.
1Understanding Texas Medicaid's Current Stance on Weight Loss Drugs
Texas Medicaid, administered by the Texas Health and Human Services Commission (HHSC), currently does not cover FDA-approved medications prescribed solely for chronic weight management under most benefit categories. This means drugs like Wegovy (semaglutide 2.4 mg) and Qsymia, which are specifically indicated for obesity treatment, are generally excluded from the Texas Medicaid formulary when the primary diagnosis is obesity (ICD-10: E66.x) alone. This exclusion aligns with a longstanding federal policy: until 2023's Treat and Reduce Obesity Act (TROA) proposals gained momentum, federal Medicaid law did not mandate coverage of weight loss drugs. Texas has not opted into expanded coverage, leaving most enrollees without a direct path to reimbursement. However, this blanket exclusion does not apply universally. Texas Medicaid operates primarily through managed care organizations (MCOs), and each MCO - including STAR, STAR+PLUS, and CHIP programs - may apply slightly different prior authorization criteria. Houston-area patients are typically served by MCOs such as UnitedHealthcare Community Plan, Molina Healthcare of Texas, and Centene's Superior HealthPlan, each of which may have nuanced formulary rules worth reviewing directly.
2The Diabetes Exception: When Ozempic May Be Covered
Here's a critical distinction that Houston patients and their physicians must understand: while Wegovy (semaglutide 2.4 mg for obesity) is generally excluded, Ozempic (semaglutide 0.5 mg–2 mg for Type 2 diabetes) is covered under Texas Medicaid when prescribed for glycemic control in patients with a confirmed Type 2 diabetes diagnosis. This matters enormously. Many Houston patients with obesity also live with Type 2 diabetes - a comorbidity that is disproportionately prevalent in Harris County and surrounding communities. If your physician documents a primary diagnosis of Type 2 diabetes (ICD-10: E11.x) and prescribes semaglutide as a glucose-lowering agent, Texas Medicaid MCOs are far more likely to approve coverage, subject to prior authorization and step-therapy requirements (typically requiring prior trials of metformin). Similarly, tirzepatide branded as Mounjaro (for T2D) may be accessible through this pathway, whereas Zepbound (tirzepatide for obesity) faces the same exclusions as Wegovy. Patients in Sugar Land and Pearland - areas with high rates of South Asian and Hispanic populations at elevated T2D risk - should discuss this dual-indication strategy carefully with a physician-supervised weight loss clinic.
3What the Clinical Trials Actually Show (STEP & SURMOUNT Data)
The clinical case for covering these medications is compelling. The STEP (Semaglutide Treatment Effect in People with Obesity) trial program, published in the New England Journal of Medicine, demonstrated that once-weekly semaglutide 2.4 mg (Wegovy) produced a mean body weight reduction of 14.9% over 68 weeks in adults with obesity or overweight with at least one weight-related comorbidity (STEP 1, Wilding et al., 2021). Participants without diabetes achieved these results alongside meaningful improvements in cardiometabolic markers. STEP 2 specifically examined patients with Type 2 diabetes, showing a 9.6% mean weight reduction - still clinically significant, and directly relevant to Houston's high T2D population. the SELECT cardiovascular outcomes trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in adults with obesity and established cardiovascular disease - a finding that helped prompt the FDA's expanded cardiovascular indication for Wegovy. For tirzepatide, the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed up to 22.5% mean body weight reduction at the 15 mg dose - the highest efficacy reported for any pharmacological weight loss treatment in a Phase 3 trial. These data underscore the medical legitimacy of coverage requests and strengthen prior authorization appeal letters.
4Texas Medicaid MCOs in Houston: Plan-by-Plan Nuances
Houston-area Medicaid enrollees are assigned to MCOs based on county and eligibility category. In Harris County and surrounding counties (Fort Bend, Montgomery, Brazoria, Galveston), the primary STAR and STAR+PLUS MCOs include: **UnitedHealthcare Community Plan of Texas** - Generally follows Texas HHSC formulary restrictions. May cover Ozempic for T2D with prior authorization. Requests for Wegovy for obesity alone are typically denied at initial submission. **Molina Healthcare of Texas** - Similar formulary stance. Molina does have a disease management program for diabetes that may facilitate faster PA approvals for semaglutide in T2D patients. **Superior HealthPlan (Centene)** - Serves a large portion of Harris County STAR members. Their pharmacy benefit manager applies step-therapy protocols; patients often must document failure on metformin and/or a sulfonylurea before GLP-1 approval. **Community Health Choice** - A Houston-founded, locally operated MCO serving Harris and surrounding counties. Their clinical pharmacists are sometimes more accessible for provider outreach, which can expedite PA decisions. Patients in The Woodlands (Montgomery County) and Katy (Harris/Fort Bend County) should confirm their assigned MCO at enrollment, as county lines affect plan availability. Call the member services number on your Medicaid card or visit YourTexasBenefits.com to verify.
5How to Build a Strong Prior Authorization Request in Texas
For Houston patients with a dual diagnosis of obesity and Type 2 diabetes, a well-prepared prior authorization (PA) request dramatically improves approval odds. Physician-supervised weight loss clinics in Houston - particularly those with bariatric medicine specialists or endocrinologists on staff - are experienced in Understanding these requests. Here's what a strong PA package typically includes: **1. Documented diagnosis:** ICD-10 codes for T2D (E11.x) and obesity (E66.x) with BMI documentation (BMI ≥30, or ≥27 with comorbidities for Wegovy; BMI ≥30 for Ozempic PA under T2D pathway). **2. Step-therapy evidence:** Records showing prior use of metformin and, if applicable, a second oral agent, with documented inadequate glycemic response (HbA1c ≥7.0% or per MCO threshold). **3. Clinical necessity letter:** A physician narrative citing relevant outcomes data - including STEP 2 or SELECT trial results - and explaining why the GLP-1 agent is medically necessary for this specific patient. **4. Comorbidity documentation:** Cardiovascular disease, hypertension, sleep apnea, or NAFLD/MASLD diagnoses strengthen medical necessity arguments considerably. If your PA is denied, you have the right to a formal appeal and, ultimately, a state fair hearing through Texas HHSC. Many Houston clinics assist patients through this process at no additional charge.
6Affordable Alternatives for Uninsured or Denied Houston Patients
If Texas Medicaid won't cover your GLP-1 medication - at least not yet - Houston-area patients are not without options. Several practical pathways can reduce out-of-pocket costs significantly: **Novo Nordisk Patient Assistance Program (PAP):** Patients with household incomes at or below 400% of the federal poverty level may qualify for Wegovy or Ozempic at no cost through Novo Nordisk's My$99Insulin-equivalent program or their NovoCare assistance line. Eligibility is income-based, not insurance-based. **Eli Lilly's LillyDirect / Insulin Value Program:** For tirzepatide (Zepbound), Lilly offers a savings card program and a direct pharmacy pathway. Uninsured list prices for Zepbound run approximately $550–$650/month, but Lilly's savings program can reduce this to around $550 for commercially insured patients. Uninsured PAP eligibility varies. **Houston Community Health Centers:** Federally Qualified Health Centers (FQHCs) in Houston - including Legacy Community Health and Avenue 360 - operate on sliding-scale fees and may have access to 340B drug pricing, which can dramatically reduce medication costs for qualifying patients. **Compounded semaglutide:** During periods of FDA-designated drug shortage, licensed compounding pharmacies may legally produce semaglutide. Houston patients should exercise caution and only use 503A/503B-accredited compounding pharmacies, as quality and dosing consistency vary.
7The Policy Horizon: Will Texas Medicaid Coverage Expand?
The federal and state policy field around GLP-1 coverage is shifting, albeit slowly. Several developments are worth tracking for Houston patients: **Treat and Reduce Obesity Act (TROA):** Repeatedly introduced in Congress, TROA would amend the Social Security Act to require Medicare and Medicaid to cover FDA-approved obesity treatments. As of early 2026, TROA has not passed, but bipartisan momentum has grown following the SELECT cardiovascular outcomes data. **Medicare's CMS Rule (2025):** CMS finalized a rule in late 2024 allowing Medicare Part D to cover anti-obesity medications for the first time starting in 2026. While this does not directly extend to Medicaid, it creates significant political pressure on states - including Texas - to align their formularies. **Texas Legislative Session (2025):** The 89th Texas Legislature considered but did not pass SB measures that would have required HHSC to cover GLP-1 medications for Medicaid enrollees with a BMI ≥40 or with serious comorbidities. Advocacy organizations like the Obesity Action Coalition are actively lobbying Austin for the next session. Houston patients and advocacy allies should monitor HHSC rulemaking updates at hhs.texas.gov and consider contacting their state representatives - particularly those representing Harris, Fort Bend, and Montgomery counties - to support coverage expansion.
8Finding a Physician-Supervised Weight Loss Clinic in Greater Houston
Understanding insurance complexity is one of the strongest reasons to work with a physician-supervised weight loss clinic rather than pursuing GLP-1 medications through a telehealth-only or med-spa provider. Board-certified bariatric physicians and obesity medicine specialists at Houston-area clinics bring several advantages: **Insurance expertise:** Established clinics maintain relationships with MCO pharmacy liaisons and have in-house staff trained in prior authorization workflows for Texas Medicaid, CHIP, and commercial plans like Blue Cross Blue Shield of Texas, Aetna, and Cigna. **Comprehensive evaluation:** GLP-1 medications carry contraindications (personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis history) that require a full medical history - something a supervised clinic provides and a telehealth platform may shortcut. **Local accountability:** Clinics in Katy, Sugar Land, Pearland, Cypress, and The Woodlands provide in-person follow-up, lab monitoring (HbA1c, lipid panels, kidney function), and dose titration guidance that optimizes safety and long-term outcomes. **Lifestyle integration:** Clinical trials including STEP 1 showed that semaglutide combined with behavioral intervention produced the best outcomes. Houston clinics offering registered dietitian support and behavioral counseling alongside medication management mirror the gold-standard trial protocols. Use the Houston Weight Loss Directory to filter clinics by suburb, insurance accepted, and specialty to find a provider that fits your coverage situation.
Texas Medicaid's coverage of GLP-1 weight loss medications remains limited in 2026 - but it is not a closed door for every Houston patient. If you have Type 2 diabetes, cardiovascular disease, or other qualifying comorbidities, a physician-supervised clinic can help build a compelling prior authorization case. Browse the Houston Weight Loss Directory today to find a local, board-certified specialist in your neighborhood who accepts your plan and can guide you through every step.
Sources & References
Clinical data referenced in this article is drawn from the FDA drug database, peer-reviewed publications (STEP trials, SURMOUNT trials), and manufacturer prescribing information for Wegovy, Ozempic, Zepbound, and Mounjaro. Pricing figures reflect publicly available estimates and may vary. Insurance coverage information is general guidance — confirm your specific benefits with your plan.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed physician before starting any weight loss medication or program.